Clinical Study Evaluating Beta Blockers Use and Fracture Risk in Patients With Primary Osteoporosis

Recruiting now · Phase 3

Conditions studied: Beta Blocker Toxicity

In brief

Clinical study evaluating selective or nonselective beta blockers use and fracture risk in patients with primary osteoporosis

Key facts

Study ID

NCT04704947

Run by

Sherief Abd-Elsalam

People needed

50

Starts

2017-10-01

Expected to finish

2030-10-01

Last updated by the study team

2021-01-12

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• • Male \& female osteoporotic patient aged ≥ 50 years
• Hypertensive \& normotensive patients
• BMD T-score ≥ 2.5 or more SD below peak bone mass

You may not qualify if…

• Patients on drugs that may improve osteoporosis disease state such as:
• Angiotensin converting enzyme inhibitor (ACEI) or Angiotensin receptor blockers (ARBs), Thiazide diuretic, Nitrates, Spironolactone, Statins.
• Patients on drugs that may worsen osteoporosis disease state such as:
• Corticosteroids, Loop diuretics, Anticonvulsants, Antidepressants, Aromatase inhibitors, Thyroid replacement therapy and Proton pump inhibitors.

Where it is running

• Sherief Abd-Elsalam — Tanta, Egypt (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.